Castle Biosciences reported earnings of -$ 0.13 per CSTL share on Nov 5, 2026, falling short of analysts' expectations by
| Report Date | Nov 5, 2026 |
|---|---|
| Forecasted EPS | -$ 0.35 |
| Earnings Per Share (Surprise) | -$ 0.13 (+$ 0.218) |
| Last Year's EPS | -$ 0.21 |
| EPS YoY Change |
Out of the last 35 earnings reporting periods, Castle Biosciences beat analysts’ expectations 19 times and fell short of expectations 9 time(s). Castle Biosciences reported earnings per share of -$ 0.13 in the last report surpassing an estimated EPS of -$ 0.35 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 5, 2026 | -$ 0.35 | -$ 0.13 | -$ 0.02 | |
| Jul 30, 2026 | -$ 0.41 | -$ 0.07 | $ 0.15 | |
| May 6, 2026 | -$ 0.49 | -$ 0.49 | -$ 0.90 | |
| Feb 26, 2026 | -$ 0.23 | -$ 0.08 | $ 0.32 | |
| Nov 3, 2025 | -$ 0.34 | -$ 0.02 | $ 0.08 | |
| Aug 4, 2025 | -$ 0.51 | $ 0.15 | $ 0.31 | |
| May 5, 2025 | -$ 0.08 | -$ 0.90 | -$ 0.09 | |
| Feb 27, 2025 | -$ 0.04 | $ 0.32 | -$ 0.10 | |
| Nov 4, 2024 | -$ 0.06 | $ 0.08 | -$ 0.26 | |
| Aug 5, 2024 | -$ 0.27 | $ 0.31 | -$ 0.70 | |
| May 2, 2024 | -$ 0.37 | -$ 0.09 | -$ 1.10 | |
| Feb 28, 2024 | -$ 0.84 | -$ 0.10 | -$ 0.78 | |
| Nov 2, 2023 | -$ 0.92 | -$ 0.26 | -$ 0.77 | |
| Aug 2, 2023 | -$ 1.01 | -$ 0.70 | -$ 0.06 | |
| May 3, 2023 | -$ 0.80 | -$ 1.10 | -$ 0.80 | |
| Feb 28, 2023 | -$ 0.91 | -$ 0.78 | -$ 0.25 | |
| Nov 2, 2022 | -$ 0.70 | -$ 0.77 | -$ 0.47 | |
| Aug 8, 2022 | -$ 0.58 | -$ 0.06 | -$ 0.34 | |
| May 9, 2022 | -$ 0.67 | -$ 0.80 | -$ 0.17 | |
| Feb 28, 2022 | -$ 0.43 | -$ 0.25 | -$ 0.16 |
Castle Biosciences’s stock was trading at $ 35.75 on Nov 4, 2026 a day before the last earnings report was released.Following the release of the earnings report, CSTL’s price decreased to $ 32.52 on Nov 6, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 5, 2026 | -$ 0.13 | $ 35.75 | $ 32.52 | |
| Jul 30, 2026 | -$ 0.07 | $ 24.46 | $ 28.00 | |
| May 6, 2026 | -$ 0.49 | $ 24.60 | $ 19.24 | |
| Feb 26, 2026 | -$ 0.08 | $ 30.83 | $ 29.57 | |
| Nov 3, 2025 | -$ 0.02 | $ 25.50 | $ 31.63 | |
| Aug 4, 2025 | $ 0.15 | $ 14.65 | $ 20.35 | |
| May 5, 2025 | -$ 0.90 | $ 19.35 | $ 16.62 | |
| Feb 27, 2025 | $ 0.32 | $ 26.04 | $ 21.68 | |
| Nov 4, 2024 | $ 0.08 | $ 33.15 | $ 31.15 | |
| Aug 5, 2024 | $ 0.31 | $ 22.28 | $ 24.90 | |
| May 2, 2024 | -$ 0.09 | $ 22.02 | $ 24.33 | |
| Feb 28, 2024 | -$ 0.10 | $ 25.09 | $ 18.06 | |
| Nov 2, 2023 | -$ 0.26 | $ 15.70 | $ 17.98 | |
| Aug 2, 2023 | -$ 0.70 | $ 16.72 | $ 18.77 | |
| May 3, 2023 | -$ 1.10 | $ 22.06 | $ 22.01 | |
| Feb 28, 2023 | -$ 0.78 | $ 24.76 | $ 22.86 | |
| Nov 2, 2022 | -$ 0.77 | $ 25.82 | $ 24.27 | |
| Aug 8, 2022 | -$ 0.06 | $ 30.56 | $ 30.64 | |
| May 9, 2022 | -$ 0.80 | $ 21.15 | $ 20.28 | |
| Feb 28, 2022 | -$ 0.25 | $ 44.69 | $ 46.70 |
Castle Biosciences released its most recent earnings reports in November 2026, July 2026, May 2026, February 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
Castle Biosciences beat analysts’ expectations during the last earnings period by
